Search results
Results from the WOW.Com Content Network
Interferon beta-1b is a cytokine in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event.
In a recent publication, REMS technology has received the attention of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases . In this work, all the available technologies for bone strength assessment and fracture risk estimation have been reviewed and discussed in relation to the ...
The more drug there is in the sample, the more free enzyme there will be, and the increased enzyme activity causes a change in color. [ 2 ] : 70 Determination of drug levels in serum is particularly important when the difference in the concentrations needed to produce a therapeutic effect and adverse side reactions (the therapeutic window ) is ...
Pharmaceutical giant Merck (NYS: MRK) reported promising results from a phase II drug trial for its new osteoporosis drug, odanacatib. Merck plans to submit applications for the drug to U.S ...
Osteoarthritis is the most common form of arthritis, affecting about 237 million people or 3.3% of the world's population as of 2015. [4] [12] It becomes more common as people age. [1] Among those over 60 years old, about 10% of males and 18% of females are affected. [2] Osteoarthritis is the cause of about 2% of years lived with disability. [12]
Bone densities are often given to patients as a T score or a Z score. A T score tells the patient what their bone mineral density is in comparison to a young adult of the same gender with peak bone mineral density. A normal T score is -1.0 and above, low bone density is between -1.0 and -2.5, and osteoporosis is -2.5 and lower.
Rebif is a disease-modifying drug (DMD) used to treat multiple sclerosis in cases of clinically isolated syndromes as well as relapsing forms of multiple sclerosis and is similar to the interferon beta protein produced by the human body. It is co-marketed by Merck Serono and Pfizer in the US under an exception to the Orphan Drug Act.
A disease-modifying osteoarthritis drug (DMOAD) is a disease-modifying drug that would inhibit or even reverse the progression of osteoarthritis. [1] Since the main hallmark of osteoarthritis is cartilage loss, a typical DMOAD would prevent the loss of cartilage and potentially regenerate it.